Employees: 983
Size AK Medical (1789.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $642M, the 685th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.65 on 18 Nov 2026.
Performance Over six months the shares fell 23.1%, against -6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue grew 16.1% over the last twelve months (peer median +16.2%); the operating margin is 26.4% (peer median 9.5%).
Valuation It trades at 10.5× forward earnings against a peer median of 27.9× (2nd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 14.3 points above its cost of capital (6.5% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.73B | HK$1.61B | HK$1.46B | HK$1.21B | HK$1.22B |
| Revenue growth | — | +10% | +21% | -1% | — |
| Gross profit | HK$1.09B | HK$948M | HK$854M | HK$729M | HK$726M |
| EBITDA | HK$582M | HK$489M | HK$413M | HK$305M | HK$358M |
| Net income | HK$420M | HK$368M | HK$297M | HK$201M | HK$238M |
| Free cash flow | HK$369M | HK$352M | HK$341M | -HK$140M | HK$170M |
| Capital expenditure | HK$89.4M | HK$134M | HK$176M | HK$217M | HK$138M |
| Total debt | n/a | HK$161M | HK$138M | HK$119M | HK$43.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1789.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.6% | -2.5% | 6th highest of 19 |
| 6-month return | -23.1% | -6.6% | 4th lowest of 19 |
| Distance from 52-week high | -35.0% | -26.0% | 7th lowest of 20 |
| Revenue growth (TTM) | +16.1% | +16.2% | 10th lowest of 20 |
| Operating margin | 26.4% | 9.5% | 5th highest of 20 |
| Forward P/E | 10.5× | 27.9× | 2nd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -11.5% | 9.3% | least demanding of 15 |
| Growth delivered (Del g) | +6.7% | +13.7% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | -18.2 pp | -3.8 pp | 5th least demanding of 15 |
| ROIC minus cost of capital | +14.3 pp | +2.5 pp | 5th highest of 20 |
| EV / EBITDA | 6.3× | 18.6× | cheapest of 9 |
| Net debt / EBITDA | -2.3× | -0.8× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 10.5× | -11.5% | +6.7% |
| Beijing Chunlizhengda Medical Instruments 1858.HK | Hong Kong | $631M | -28% | -9% | 31% | 8.5× | -9.5% | +1.5% |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | n/a | -2.6% | +18.8% |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 10.7× | n/a | n/a |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 13.8× | 0.2% | +47.5% |
| Shanghai Kinetic Medical 300326.SZ | China | $662M | -10% | -28% | 17% | 26.0× | 6.6% | -1.9% |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $680M | -9% | +29% | 5% | 39.0× | 10.1% | +14.2% |
| Delcath Systems DCTH | United States | $685M | +75% | +38% | 5% | 358.9× | 33.4% | +120.2% |
| Livsmed 491000.KS | South Korea | $687M | -47% | +89% | -77% | n/a | n/a | n/a |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Shenzhen Lifotronic Technology 688389.SS | China | $692M | -14% | +14% | 13% | 29.9× | 11.6% | +13.3% |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai Sanyou Medical 688085.SS | China | $692M | -23% | +15% | 4% | 50.0× | 29.0% | +6.8% |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $697M | +148% | -14% | 3% | n/a | 31.8% | -0.6% |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |